$SNOA News

Sonoma Pharmaceuticals Enters Underwriting Agreement With Dawson James Securities On April 24, 2026; To Issue 2,962,962 Units At $1.35 Per Unit In Public Offering

What's Going On With Sonoma Pharma Stock Monday?

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Sonoma Pharmaceuticals shares are trading lower after the company priced a $4 million public offering.

Sonoma Pharmaceuticals shares are trading lower after the company priced a $4 million public offering.

Sonoma Pharmaceuticals Prices Offering Of 2,962,963 Shares And Accompanying Warrants At $1.35 Per Unit

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Q3 EPS $(0.48) Misses $(0.31) Estimate, Sales $4.349M Beat $4.326M Estimate

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

Sonoma Pharmaceuticals And Partner MicroSafe Care Receive Australian Therapeutic Goods Administration Approval For Its Nanocyn Advanced Disinfectant & Sanitizer

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Q2 EPS $(0.32) Misses $(0.31) Estimate, Sales $5.604M Beat $4.261M Estimate

Sonoma Pharmaceuticals Terminates EVP And COO Bruce Thornton For Cause, Effective October 18, 2025

Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

Sonoma Pharmaceuticals Highlights FDA Cosmetic Product Facility Registration, Microcyn-Based Cosmetic Product Listing Under MoCRA

Sonoma Pharmaceuticals Enters At Market Issuance Sales Agreement With Ladenburg; To Pay 3% Commission To Ladenburg On Share Sales